Toan M. Le

Array ( [id] => 19300072 [patent_doc_number] => 20240228641 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => ANTIBODIES BINDING TO CD30 AND CD3 [patent_app_type] => utility [patent_app_number] => 18/478711 [patent_app_country] => US [patent_app_date] => 2023-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18478711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19300072 [patent_doc_number] => 20240228641 [patent_country] => US [patent_kind] => A9 [patent_issue_date] => 2024-07-11 [patent_title] => ANTIBODIES BINDING TO CD30 AND CD3 [patent_app_type] => utility [patent_app_number] => 18/478711 [patent_app_country] => US [patent_app_date] => 2023-09-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 31194 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18478711 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18923410 [patent_doc_number] => 20240026414 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => Compositions and Methods for Peptide Production [patent_app_type] => utility [patent_app_number] => 18/477276 [patent_app_country] => US [patent_app_date] => 2023-09-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18290 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18477276 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19097772 [patent_doc_number] => 20240117000 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-11 [patent_title] => GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/459394 [patent_app_country] => US [patent_app_date] => 2023-08-31 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 30937 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18459394 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19083174 [patent_doc_number] => 20240109975 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => BCMA ANTIBODIES AND USE OF SAME TO TREAT CANCER AND IMMUNOLOGICAL DISORDERS [patent_app_type] => utility [patent_app_number] => 18/449876 [patent_app_country] => US [patent_app_date] => 2023-08-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22123 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18449876 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19156136 [patent_doc_number] => 20240148843 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-05-09 [patent_title] => Peptide [patent_app_type] => utility [patent_app_number] => 18/448678 [patent_app_country] => US [patent_app_date] => 2023-08-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6782 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18448678 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18784648 [patent_doc_number] => 20230372237 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-23 [patent_title] => THERAPEUTIC AGENT PREPARATIONS FOR DELIVERY INTO A LUMEN OF THE INTESTINAL TRACT USING A SWALLOWABLE DRUG DELIVERY DEVICE [patent_app_type] => utility [patent_app_number] => 18/230086 [patent_app_country] => US [patent_app_date] => 2023-08-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 27260 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18230086 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19127271 [patent_doc_number] => 20240132624 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-25 [patent_title] => POLYPEPTIDES BINDING TO A SPECIFIC EPITOPE OF THE NEONATAL FC RECEPTOR [patent_app_type] => utility [patent_app_number] => 18/360393 [patent_app_country] => US [patent_app_date] => 2023-07-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 54504 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18360393 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18901413 [patent_doc_number] => 20240016898 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-18 [patent_title] => TREATMENT OF EXERCISE-INDUCED HYPOGLYCEMIA IN TYPE 1 AND INSULIN USING TYPE 2 DIABETES [patent_app_type] => utility [patent_app_number] => 18/357666 [patent_app_country] => US [patent_app_date] => 2023-07-24 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11155 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18357666 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 20715566 [patent_doc_number] => 12630803 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2026-05-19 [patent_title] => Method of increasing proliferation of pancreatic beta cells, treatment method, and composition [patent_app_type] => utility [patent_app_number] => 18/354452 [patent_app_country] => US [patent_app_date] => 2023-07-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 25 [patent_no_of_words] => 11252 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18354452 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18921501 [patent_doc_number] => 20240024505 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-01-25 [patent_title] => SYNTHETIC CELLULAR SIGNALING PATHWAYS AND USES THEREOF [patent_app_type] => utility [patent_app_number] => 18/221206 [patent_app_country] => US [patent_app_date] => 2023-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 50084 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -18 [patent_words_short_claim] => 50 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18221206 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19081930 [patent_doc_number] => 20240108731 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-04-04 [patent_title] => THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 [patent_app_type] => utility [patent_app_number] => 18/345832 [patent_app_country] => US [patent_app_date] => 2023-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 20125 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -8 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18345832 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18806987 [patent_doc_number] => 20230381320 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-11-30 [patent_title] => THERAPEUTIC DERIVATIVES OF INTERLEUKIN-22 [patent_app_type] => utility [patent_app_number] => 18/345775 [patent_app_country] => US [patent_app_date] => 2023-06-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19973 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 86 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18345775 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18709190 [patent_doc_number] => 20230331802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-19 [patent_title] => METHOD TO PREPARE THERAPEUTICALLY ACTIVE ALDESLEUKIN HIGHLY STABLE IN LIQUID PHARMACEUTICAL COMPOSITIONS [patent_app_type] => utility [patent_app_number] => 18/344130 [patent_app_country] => US [patent_app_date] => 2023-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 6946 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -17 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18344130 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19265373 [patent_doc_number] => 20240209072 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-06-27 [patent_title] => Method of Reducing Blood Glucose Levels and Inhibiting Secreted aP2 [patent_app_type] => utility [patent_app_number] => 18/341404 [patent_app_country] => US [patent_app_date] => 2023-06-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 9452 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 34 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18341404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19310490 [patent_doc_number] => 12036284 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2024-07-16 [patent_title] => Compositions and methods of treatment for severe hypertriglyceridemia [patent_app_type] => utility [patent_app_number] => 18/340421 [patent_app_country] => US [patent_app_date] => 2023-06-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 46 [patent_figures_cnt] => 46 [patent_no_of_words] => 32164 [patent_no_of_claims] => 27 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 196 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18340421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18724349 [patent_doc_number] => 20230338491 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => METHOD FOR SCREENING INDIVIDUAL TUMOR NEOANTIGEN PEPTIDE, AND VACCINE FORMULATION THEREOF [patent_app_type] => utility [patent_app_number] => 18/338605 [patent_app_country] => US [patent_app_date] => 2023-06-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8156 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -10 [patent_words_short_claim] => 665 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18338605 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18723941 [patent_doc_number] => 20230338060 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-10-26 [patent_title] => Device and Method for Treating Osteonecrosis [patent_app_type] => utility [patent_app_number] => 18/334212 [patent_app_country] => US [patent_app_date] => 2023-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12767 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 89 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18334212 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 18656210 [patent_doc_number] => 20230302094 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2023-09-28 [patent_title] => GLP-1 RECEPTOR AGONISTS IN DEMENTIA [patent_app_type] => utility [patent_app_number] => 18/208485 [patent_app_country] => US [patent_app_date] => 2023-06-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 13601 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -21 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18208485 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 19359294 [patent_doc_number] => 20240261328 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2024-08-08 [patent_title] => USE OF CART19 TO DEPLETE NORMAL B CELLS TO INDUCE TOLERANCE [patent_app_type] => utility [patent_app_number] => 18/332150 [patent_app_country] => US [patent_app_date] => 2023-06-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 14563 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -9 [patent_words_short_claim] => 63 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 18332150 [rel_patent_id] =>[rel_patent_doc_number] =>)